|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2002-10-4
|
|
pubmed:abstractText |
A pharmacokinetic-pharmacodynamic study of a long-acting GH [Nutropin Depot; somatropin (rDNA origin) for injectable suspension] was performed in 25 patients with adult GH deficiency. Single doses of 0.25 mg/kg and 0.5 mg/kg, based on ideal body weight, were administered sc. After either dose, serum GH concentrations rose rapidly in both sexes. In men, the lower dose maintained serum IGF-I levels within 1 SD of the mean for age and sex for 14-17 d; the higher dose raised IGF-I levels 2 SD above the mean. In most women, all of whom were receiving oral estrogen, the lower dose did not normalize IGF-I levels; the higher dose maintained IGF-I near the mean for approximately 14 d. Increases in IGF binding protein-3 and acid-labile subunit levels were observed in both sexes; however, a sex-related difference was not obvious. Fasting glucose and insulin concentrations were transiently elevated in men receiving the higher dose. Patients tolerated the injections well. We concluded that a single injection of Nutropin Depot at these doses in patients with adult GH deficiency increased serum IGF-I to within normal limits for 14-17 d. Estrogen-treated women required approximately twice the dose needed in men to produce comparable IGF-I concentrations.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0021-972X
|
|
pubmed:author |
pubmed-author:AttieK MKM,
pubmed-author:BenzigerD PDP,
pubmed-author:BillerB M KBM,
pubmed-author:BlethenS LSL,
pubmed-author:CookD MDM,
pubmed-author:DaleC RCR,
pubmed-author:FielderP JPJ,
pubmed-author:HoffmanA RAR,
pubmed-author:IlleperumaAA,
pubmed-author:PalH KHK,
pubmed-author:PhillipsL SLS,
pubmed-author:ReimannJ DJD,
pubmed-author:VanceM LML
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
87
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
4508-14
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:12364427-Adult,
pubmed-meshheading:12364427-Aged,
pubmed-meshheading:12364427-Blood Glucose,
pubmed-meshheading:12364427-Carrier Proteins,
pubmed-meshheading:12364427-Delayed-Action Preparations,
pubmed-meshheading:12364427-Fasting,
pubmed-meshheading:12364427-Female,
pubmed-meshheading:12364427-Glycoproteins,
pubmed-meshheading:12364427-Human Growth Hormone,
pubmed-meshheading:12364427-Humans,
pubmed-meshheading:12364427-Insulin,
pubmed-meshheading:12364427-Insulin-Like Growth Factor Binding Protein 3,
pubmed-meshheading:12364427-Insulin-Like Growth Factor I,
pubmed-meshheading:12364427-Kinetics,
pubmed-meshheading:12364427-Male,
pubmed-meshheading:12364427-Middle Aged,
pubmed-meshheading:12364427-Sex Characteristics
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
The pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (nutropin depot) in GH-deficient adults.
|
|
pubmed:affiliation |
Department of Medicine, Oregon Health Sciences University, Portland, Oregon 97201, USA. cookd@ohsu.edu
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
